/
Biological products, (no diagnostic substances) company · NV · FY ends Oct · Revenue $6M · -90.21% margin · -$1M FCF
The business is unprofitable at the operating level (-103.60% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 12.5% YoY with margins expanding 11.5pp.
Negative free cash flow of -$741K. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$6M
▲ +12.5% YoY
Net Income (TTM)
-$5M
▼ -17.3% YoY
Op. Margin
-90.21%
▲ +11.5pp YoY
ROIC
-378.73%
Cash Flow & Balance Sheet
FCF (TTM)
-$1M
▲ +48.9% YoY
Op. Cash Flow (TTM)
-$1M
▲ +50.5% YoY
Net Debt
-$431K
Net Cash Position
Cash & Equiv.
$1M
5Y CAGR: +11.2%
Continue Research